Home › Research › Treatments
Lecanemab and Donanemab Combination Therapy for Alzheimer’s Disease-The Cocktail May Work Even Better Together
Eric Dinnerstein. Alzheimer Disease & Associated Disorders, 2026-01-01
Topic: Amyloid, tau and blood-test diagnosis
Lecanemab and Donanemab are two new FDA-approved antiamyloid immunotherapies that are Alzheimer disease modifying agents. They do not work on the same target, however. While Lecanemab targets pathologic amyloid protofibrils, Donanemab targets the amyloid plaque itself intracranially. In theory, they can be administered together, as combination therapy, to produce an augmented effect. Research of the feasibility of such a combination will require bringing together competing pharmaceutical companies, which can only happen by setting a national agenda bringing together academia, pharma, the government and advocacy groups.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dinnerstein, E. (2026). Lecanemab and Donanemab Combination Therapy for Alzheimer’s Disease-The Cocktail May Work Even Better Together. Alzheimer Disease & Associated Disorders. https://doi.org/10.1097/wad.0000000000000711
Vancouver
Dinnerstein E. Lecanemab and Donanemab Combination Therapy for Alzheimer’s Disease-The Cocktail May Work Even Better Together. Alzheimer Disease & Associated Disorders. 2026. doi:10.1097/wad.0000000000000711. PMID: 41773886.
BibTeX
@article{dinnerstein2026-41773886,
author = {Dinnerstein, Eric},
title = {{Lecanemab and Donanemab Combination Therapy for Alzheimer’s Disease-The Cocktail May Work Even Better Together}},
journal = {Alzheimer Disease \& Associated Disorders},
year = {2026},
doi = {10.1097/wad.0000000000000711},
pmid = {41773886},
url = {https://doi.org/10.1097/wad.0000000000000711}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Lecanemab and Donanemab are two new FDA-approved antiamyloid immunotherapies that are Alzheimer disease modifying agents.
- They do not work on the same target, however.
- While Lecanemab targets pathologic amyloid protofibrils, Donanemab targets the amyloid plaque itself intracranially.
- In theory, they can be administered together, as combination therapy, to produce an augmented effect.
- Research of the feasibility of such a combination will require bringing together competing pharmaceutical companies, which can only happen by setting a national agenda bringing together academia, pharma, the government and advocacy groups.
Why it matters
Lecanemab targets amyloid protofibrils while donanemab targets the amyloid plaque itself, so in theory they could be given together as combination therapy for an augmented effect. Testing this would require competing pharmaceutical companies to work together, which the authors say needs a national agenda.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 27 of the 97 points we could judge it on, which is 28 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer Disease & Associated Disorders) |
| Journal's citation record | 1 / 4 | Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Eric Dinnerstein: h-index 6 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41773886) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 27 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 27 of the 97 points we could judge it on is 28 out of 100. |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments
Also tagged “placebo-controlled”
783 studies in the library carry the topic tag “placebo-controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.